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There are a number of systemic diseases with cardiovascular 
manifestations in which echocardiography plays a valuable role 
for surveillance and follow-up of anticipated cardiovascular ab-
normalities. Systemic autoimmune disorders are frequently as-
sociated to cardiac involvement such as pericarditis, myocardi-
tis, valvular abnormalities or ischemic coronary disease. 
Ankylosing spondylitis (AS) is also a chronic systemic in-
flammatory rheumatic disorder that primarily affects the axial 
joints and mainly involves young male. Extra-articular mani-
festations vary widely in terms of both frequency and severity. 
The most common extra-articular manifestations are uveitis, 
bowel disease, skin, lung and kidney involvement; less fre-
quently cardiovascular involvement occurs.1) Screening for ex-
tra-articular manifestations in patients with AS is important 
for appropriate management as the presence of extra-articular 
manifestations may be a consequence of uncontrolled systemic 
inflammation and may influence treatment decisions.2) The 
prevalence of cardiac pathologies in patients with AS has been 
reported to be 10% to 30%.3) It is related to a sclerosing in-
flammatory process that primarily involves the aortic root and 
the aortic valve, and the chronic inflammation may extend 
into the ventricular septum, atrioventricular node, proximal 
bundle of His and bundle branches or fascicles. Thus, various 
studies indicate a higher rate of conduction disturbances, val-
vular heart disease and ascending aortic involvement in pa-
tients with AS compared with the normal population.4)  
In this issue of the journal, Park et al.5) reported the early 
valvular and aortic involvement in young male patients with 
AS using transesophageal echocardiography. A total of 70 AS 
patients were divided into AS group I (< 10 years of disease 
duration) and AS group II (≥ 10 years) depending on their dis-
ease duration after the first diagnosis. The thickness of aortic 
valve was increased in AS patients than in control (control vs. 
AS group I vs. AS group II, 1.2 ± 0.3 vs. 1.8 ± 0.7 vs. 2.1 ± 
0.8 mm, p < 0.01). The thickness of mitral valve was also in-
creased in AS patients (control vs. AS group I vs. AS group II, 
0.9 ± 0.1 vs. 1.2 ± 0.3 vs. 1.2 ± 0.4 mm, p < 0.01). Aortic 
root diameter at the sinus of Valsalva was slightly increased in 
AS group II. Furthermore, aortic strain and distensibility were 
decreased and aortic stiffness beta index was increased in AS 
group II compared with control and AS group I. Mitral annu-
lus early diastolic velocity (E’) and systolic velocity (S’) by tis-
sue Doppler imaging were slightly decreased in AS group II. 
However there was no increased rate for valvular regurgitation 
(aortic and mitral valve) and for conduction disturbances. 
There are some limitations in this study. As they described, 
the design of this study was observational and cross-sectional, 
and conducted in a single center. The clinical significance of 
the results is unclear in this design. Thus a large long-term 
prospective study is needed to elucidate the clinical signifi-
cance of early changes in valve, aorta and myocardial function. 
There was no age-matched control group for AS group II. 
Mean ages of both control and AS group I were 27 years. 
However mean age of AS group II was 34 years. Thus it is un-
clear whether the slight differences in parameters of tissue 
Doppler and aortic stiffness were from difference of disease du-
ration or from difference of age. Finally the effects of disease 
activities and drug therapy for AS on cardiac and aortic abnor-
malities were not fully evaluated in this study. 
Despite the limitations, Park et al’s study5) give us useful 
informations about early subclinical changes of aorto-mitral 
valve and aortic stiffness in AS patients in the era of advanced 
management of AS with immunosuppressive and/or immune-
modulating drugs.
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